The Grassroots of Business Success

Malignant pleural mesothelioma is a rare and fast moving tumor for which no successful remedy exists notwithstanding the breakthrough of quite a few likely genetic targets. The late stages of Malignant pleural mesothelioma diagnosis and the long period of time that exists between exposures and diagnosis have made it hard to comprehensively evaluate the role of risk factors and their downstream molecular effects.

Many hospitals are now seeing an increasing amount of patients that have peritoneal cancer. This gives pathologists diagnosing the patient many problems, that are divided into those exposed in finding the differences between malignant mesothelioma and harmless changes and those seen in differentiating cancer of the mesothelium from additional forms of epithelial and tissue tumors that connect. Immunohistochemistry plays a major role in helping to make the diagnosis, nevertheless it should be interpreted in regards to the scientific setting and radiological features, and with an understanding of the extensive morphological variations existing in malignant mesothelioma.

Malignant mesothelioma is a cancer affecting the serosal cavities, an anatomic location that is often affected by metastatic disease, largely from primary cancers of the breast, ovary and lung. Progression in immunohistochemistry have caused an enhanced diagnostic sensitivity and mesothelioma in both cytological and histological material. Recently, the authors group used increased levels of throughput technology to the recognition of new signs that might assist in being able to tell the difference between cancer of the mesothelium from ovarian and peritoneal serous carcinoma, tumors cells that contain closely related histogenesis and antigenic profile. Together with the improved medical devices available for serosal cancer diagnosis, understanding the biology of cancer of the mesothelium has increased lately.

Washington DC council member David Catania actually suggested that the council should consider claiming eminent domain of certain widely prescribed pharmaceutical formulas in order to help reign in rising drug costs for the city. Catania suggests that the patents should be acquired by the government through the mayor’s declaration of a public health emergency and then generic manufacturers would be contacted to produce the drugs for cheaper than they are commercially available.

There are so many things wrong with this proposal that it is hard to decide where to begin. First off, convincing anyone that there is a public health emergency due to the cost of medicines is absolutely ridiculous. The cost of health care does need to be addressed in order for our economy to thrive, but when one breaks down the actual costs of health care one finds that medications account for only 10 percent of the overall health care spending. What would be next, claiming eminent domain over hospitals so the government can set the prices that they are allowed to charge?

Also, what Catania fails to realize is that even under eminent domain claims the government is still required to pay the fair market value to the person/entity that they are seizing the property from, so not only would they need to pay for the intellectual rights to the drugs, the government would then need to pay a generic company to produce and get approval from the FDA to sell the drug which would basically wipe out any savings Catania would hope to realize.

The eminent domain seizure of the patents of drugs would all but guarantee that pharmaceutical companies in this country would have no incentive to develop new drugs, so one hopes that all the drugs required to treat any future aliments have already been discovered. Getting these drugs cheaply now, comes at the very expensive cost of losing any future developments from pharmaceutical companies.

Daniel Spankie is the creator/editor of http://www.Chemtracker.net, a Pharmaceutical news forum for professionals.